Inventor · disambiguated record
Stefan Endres
Also filed as: ENDRES STEFAN
6 granted patents·4 pending applications·25 citations·filing 2003–2022
77Inventor score
Files withHOFFMANN LA ROCHE3UNIV MUENCHEN LUDWIG MAXIMILIANS2ALNYLAM PHARMACEUTICALS INC1HARTMANN GUNTHER1KLINIKUM DER UNIV MUNCHEN1
Top patents by PatentIndex Score
10 records- 0189US11732052B2Bispecific antibody molecules with antigen-transfected T-cells and their use in medicineHOFFMANN LA ROCHE·Filed 2020·Granted Aug 22, 2023·3 cites·19 claims
- 0289US8003619B2Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotideALNYLAM PHARMACEUTICALS INC·Filed 2005·Granted Aug 23, 2011·16 cites·22 claims
- 0380US10633451B2Bispecific antibody molecules with antigen-transfected T-cells and their use in medicineHOFFMANN LA ROCHE·Filed 2013·Granted Apr 28, 2020·4 cites·16 claims
- 0475US11192935B2PD-1-CD28 fusion proteins and their use in medicineKOBOLD SEBASTIAN·Filed 2016·Granted Dec 7, 2021·2 cites·11 claims
- 0556US2024342282A1Anti-csf1r car expressing lymphocytes for targeted tumor therapyUNIV MUENCHEN LUDWIG MAXIMILIANS·Filed 2022·Application pending·0 cites
- 0645US11723922B2CXCR6-transduced T cells for targeted tumor therapyUNIV MUENCHEN LUDWIG MAXIMILIANS·Filed 2016·Granted Aug 15, 2023·0 cites·6 claims
- 0745US2012045461A1Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAsHARTMANN GUNTHER·Filed 2011·Application pending·0 cites
- 0843US2022143087A1Ccr8 expressing lymphocytes for targeted tumor therapyKLINIKUM DER UNIV MUNCHEN·Filed 2020·Application pending·0 cites
- 0939US11547748B2Adoptive t-cell therapyHOFFMANN LA ROCHE·Filed 2017·Granted Jan 10, 2023·0 cites·24 claims
- 1037US2003228278A1Immunotherapy of chronic infections and of malignant diseasesFiled 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stefan Endres files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →